Copyright Reports & Markets. All rights reserved.

Global Pulmonary Fibrosis Drug Market Research Report 2021

Request for Sample of this report
Buy now

1 Pulmonary Fibrosis Drug Market Overview

  • 1.1 Product Overview and Scope of Pulmonary Fibrosis Drug
  • 1.2 Pulmonary Fibrosis Drug Segment by Type
    • 1.2.1 Global Pulmonary Fibrosis Drug Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Pirfenidone
    • 1.2.3 Nintedanib
  • 1.3 Pulmonary Fibrosis Drug Segment by Application
    • 1.3.1 Pulmonary Fibrosis Drug Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hospital
    • 1.3.3 Clinic
  • 1.4 Global Pulmonary Fibrosis Drug Market Size Estimates and Forecasts
    • 1.4.1 Global Pulmonary Fibrosis Drug Revenue 2016-2027
    • 1.4.2 Global Pulmonary Fibrosis Drug Sales 2016-2027
    • 1.4.3 Pulmonary Fibrosis Drug Market Size by Region: 2016 Versus 2021 Versus 2027

2 Pulmonary Fibrosis Drug Market Competition by Manufacturers

  • 2.1 Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Pulmonary Fibrosis Drug Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Pulmonary Fibrosis Drug Manufacturing Sites, Area Served, Product Type
  • 2.5 Pulmonary Fibrosis Drug Market Competitive Situation and Trends
    • 2.5.1 Pulmonary Fibrosis Drug Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Pulmonary Fibrosis Drug Players Market Share by Revenue
    • 2.5.3 Global Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Pulmonary Fibrosis Drug Retrospective Market Scenario by Region

  • 3.1 Global Pulmonary Fibrosis Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Pulmonary Fibrosis Drug Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Pulmonary Fibrosis Drug Market Facts & Figures by Country
    • 3.3.1 North America Pulmonary Fibrosis Drug Sales by Country
    • 3.3.2 North America Pulmonary Fibrosis Drug Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Pulmonary Fibrosis Drug Market Facts & Figures by Country
    • 3.4.1 Europe Pulmonary Fibrosis Drug Sales by Country
    • 3.4.2 Europe Pulmonary Fibrosis Drug Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Pulmonary Fibrosis Drug Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Pulmonary Fibrosis Drug Sales by Region
    • 3.5.2 Asia Pacific Pulmonary Fibrosis Drug Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Pulmonary Fibrosis Drug Market Facts & Figures by Country
    • 3.6.1 Latin America Pulmonary Fibrosis Drug Sales by Country
    • 3.6.2 Latin America Pulmonary Fibrosis Drug Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Pulmonary Fibrosis Drug Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Pulmonary Fibrosis Drug Sales by Country
    • 3.7.2 Middle East and Africa Pulmonary Fibrosis Drug Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Pulmonary Fibrosis Drug Historic Market Analysis by Type

  • 4.1 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2016-2021)
  • 4.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2016-2021)
  • 4.3 Global Pulmonary Fibrosis Drug Price by Type (2016-2021)

5 Global Pulmonary Fibrosis Drug Historic Market Analysis by Application

  • 5.1 Global Pulmonary Fibrosis Drug Sales Market Share by Application (2016-2021)
  • 5.2 Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2016-2021)
  • 5.3 Global Pulmonary Fibrosis Drug Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Boehringer Ingelheim
    • 6.1.1 Boehringer Ingelheim Corporation Information
    • 6.1.2 Boehringer Ingelheim Description and Business Overview
    • 6.1.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Boehringer Ingelheim Product Portfolio
    • 6.1.5 Boehringer Ingelheim Recent Developments/Updates
  • 6.2 Roche
    • 6.2.1 Roche Corporation Information
    • 6.2.2 Roche Description and Business Overview
    • 6.2.3 Roche Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Roche Product Portfolio
    • 6.2.5 Roche Recent Developments/Updates
  • 6.3 FibroGen, Inc.
    • 6.3.1 FibroGen, Inc. Corporation Information
    • 6.3.2 FibroGen, Inc. Description and Business Overview
    • 6.3.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 FibroGen, Inc. Product Portfolio
    • 6.3.5 FibroGen, Inc. Recent Developments/Updates
  • 6.4 Merck & Co., Inc.
    • 6.4.1 Merck & Co., Inc. Corporation Information
    • 6.4.2 Merck & Co., Inc. Description and Business Overview
    • 6.4.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Merck & Co., Inc. Product Portfolio
    • 6.4.5 Merck & Co., Inc. Recent Developments/Updates
  • 6.5 Bristol-Myers Squibb Company
    • 6.5.1 Bristol-Myers Squibb Company Corporation Information
    • 6.5.2 Bristol-Myers Squibb Company Description and Business Overview
    • 6.5.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Bristol-Myers Squibb Company Product Portfolio
    • 6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
  • 6.6 MediciNova, Inc.
    • 6.6.1 MediciNova, Inc. Corporation Information
    • 6.6.2 MediciNova, Inc. Description and Business Overview
    • 6.6.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 MediciNova, Inc. Product Portfolio
    • 6.6.5 MediciNova, Inc. Recent Developments/Updates
  • 6.7 Genentech, Inc.
    • 6.6.1 Genentech, Inc. Corporation Information
    • 6.6.2 Genentech, Inc. Description and Business Overview
    • 6.6.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Genentech, Inc. Product Portfolio
    • 6.7.5 Genentech, Inc. Recent Developments/Updates
  • 6.8 Cipla Inc.
    • 6.8.1 Cipla Inc. Corporation Information
    • 6.8.2 Cipla Inc. Description and Business Overview
    • 6.8.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Cipla Inc. Product Portfolio
    • 6.8.5 Cipla Inc. Recent Developments/Updates
  • 6.9 Biogen
    • 6.9.1 Biogen Corporation Information
    • 6.9.2 Biogen Description and Business Overview
    • 6.9.3 Biogen Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Biogen Product Portfolio
    • 6.9.5 Biogen Recent Developments/Updates
  • 6.10 Galapagos NV
    • 6.10.1 Galapagos NV Corporation Information
    • 6.10.2 Galapagos NV Description and Business Overview
    • 6.10.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Galapagos NV Product Portfolio
    • 6.10.5 Galapagos NV Recent Developments/Updates

7 Pulmonary Fibrosis Drug Manufacturing Cost Analysis

  • 7.1 Pulmonary Fibrosis Drug Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Pulmonary Fibrosis Drug
  • 7.4 Pulmonary Fibrosis Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Pulmonary Fibrosis Drug Distributors List
  • 8.3 Pulmonary Fibrosis Drug Customers

9 Pulmonary Fibrosis Drug Market Dynamics

  • 9.1 Pulmonary Fibrosis Drug Industry Trends
  • 9.2 Pulmonary Fibrosis Drug Growth Drivers
  • 9.3 Pulmonary Fibrosis Drug Market Challenges
  • 9.4 Pulmonary Fibrosis Drug Market Restraints

10 Global Market Forecast

  • 10.1 Pulmonary Fibrosis Drug Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Type (2022-2027)
  • 10.2 Pulmonary Fibrosis Drug Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Application (2022-2027)
  • 10.3 Pulmonary Fibrosis Drug Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Pulmonary Fibrosis Drug by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Pulmonary Fibrosis Drug by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Pirfenidone
    Nintedanib

    Segment by Application
    Hospital
    Clinic

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Boehringer Ingelheim
    Roche
    FibroGen, Inc.
    Merck & Co., Inc.
    Bristol-Myers Squibb Company
    MediciNova, Inc.
    Genentech, Inc.
    Cipla Inc.
    Biogen
    Galapagos NV

    Buy now